Potential therapies for cisplatin-induced AKI based on pathophysiological mechanisms of injury include EPO (inhibits tubular apoptosis), MSCs, cytokine inhibitors (TNF-α or IL-33 inhibitors), inhibitors of the MAPK pathway, inhibitors of oxidant stress, and anti-inflammatory agents that can reduce CD4+ T cells. Here, IL33 is linked to acute kidney injury.